DREAMM-20
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 152 patients (estimated)
- Sponsors
- GlaxoSmithKline
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1354
- NCT Identifier
- NCT05714839
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.